Ignite Creation Date:
2024-05-06 @ 8:03 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06238024
Status:
COMPLETED
Last Update Posted:
2024-02-06
First Post:
2024-01-15
Brief Title:
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Sponsor:
Suzhou Municipal Hospital of Anhui Province
Organization:
Suzhou Municipal Hospital of Anhui Province
Study Overview
Official Title:
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment a Double-blind Randomized Placebo-controlled Trial
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IRIS
Brief Summary:
Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment
Detailed Description:
Vascular recanalization techniques including thrombolysis and thrombectomy have become the mainstay of treatment for acute ischemic stroke However some patients still experience poor prognosis with ineffective recanalization and reperfusion brain injury being the major contributors to unfavorable outcomes Studies have indicated that tocilizumab used in ST-segment elevation and non-ST-segment elevation myocardial infarction exhibits anti-inflammatory and myocardial protective effects Nevertheless whether tocilizumab can provide neuroprotection in the early stages of acute large vessel recanalization remains uncertain Given the above evidence the aim of this study was to investigate whether combination therapy with tocilizumab in the early phase of recanalization of acute large vessel occlusion could further exert a beneficial effect and thus improve the poor prognosis of patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None